TGR5 activation has also emerged as a promising therapeutic target in inflammatory bowel disease (IBD), particularly in the context of obesity-associated intestinal inflammation. This evidence concerns the gene GPBAR1 and obesity due to melanocortin 4 receptor deficiency.